Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.67 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.55 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 10/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3162634 | 0.84 | KDM4E (0.72) | KDM4EALDH1A1HPGDCLK4GABRA1 | |
| SCHEMBL4656063 | 0.84 | BRAF (0.73) | KDM4EBRAF | |
| SCHEMBL30579781 | 0.81 | KDM4E (0.71) | KDM4EALDH1A1HPGDCLK4GABRA1 | |
| SCHEMBL3164198 | 0.81 | KDM4E (0.69) | KDM4EBRAFCYP17A1 | |
| SCHEMBL9468075 | 0.81 | KDM4E (0.69) | KDM4EBRAFCYP17A1 | |
| SCHEMBL5804188 | 0.81 | KDM4E (0.71) | KDM4EALDH1A1HPGDCLK4GABRA1 | |
| SCHEMBL3155574 | 0.81 | KDM4E (0.69) | KDM4EBRAFCYP17A1 | |
| SCHEMBL9468711 | 0.81 | KDM4E (0.71) | KDM4EALDH1A1HPGDCLK4GABRA1 | |
| SCHEMBL30579799 | 0.81 | KDM4E (0.71) | KDM4EALDH1A1HPGDCLK4GABRA1 | |
| SCHEMBL9468197 | 0.81 | KDM4E (0.71) | KDM4EALDH1A1HPGDCLK4GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713808-B1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC (US) | 2010-02-24 | — | — | EP | claimed |
| US-7498434-B2 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC (US) | 2009-03-03 | — | — | US | claimed |
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC, (US) | 2007-07-05 | — | — | US | claimed |
| US-4178449-A | Pyrazolo[1,5-a]pyrimidines and imidazo-[1,5-a]pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1979-12-11 | — | — | US | claimed |
| US-7498434-B2 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC (US) | 2009-03-03 | — | — | US | disclosed |
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC, (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1713808-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT, INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070931-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-5219857-A | Method of treating cognitive and related neural behavioral problems | AMERICAN CYANAMID COMPANY (US) | 1993-06-15 | — | — | US | disclosed |
| US-5169850-A | Neurotropic or hypotensive agents | AMERICAN CYANAMID COMPANY (US) | 1992-12-08 | — | — | US | disclosed |
| US-5126340-A | Antidepressants | AMERICAN CYANAMID COMPANY (US) | 1992-06-30 | — | — | US | disclosed |
| US-5059691-A | Anxiolytic agents; hypotensive agents; nervous system disorders; cognition activators | AMERICAN CYANAMID COMPANY (US) | 1991-10-22 | — | — | US | disclosed |
| US-4963553-A | TREATING COGNITIVE AND NEURAL BEHAVIORAL PROBLEMS IN MAMMALS | AMERICAN CYANAMID CO. (US) | 1990-10-16 | — | — | US | disclosed |
| US-4916137-A | 5-(Substituted-amino)-8-(phenyl or substituted-phenyl)-3H,6H-1,4,5A,8A-tetraazaacenaphthylen-3-ones and treatment of neural behavior disorders | AMERICAN CYANAMID COMPANY (US) | 1990-04-10 | — | — | US | disclosed |
| US-4847256-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0264773-A1 | 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1988-04-27 | — | — | EP | disclosed |
| US-4236005-A | ANTIANXIETY | AMERICAN CYANAMID COMPANY (US) | 1980-11-25 | — | — | US | disclosed |
| US-4178449-A | Pyrazolo[1,5-a]pyrimidines and imidazo-[1,5-a]pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1979-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | AZI2, CDK2, TPMT | KDM4E 3705/4885ALDH1A1 1128/4885HPGD 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.